Paul Porter, MD
Internal Medicine · Portland, TNNPI 1134154461
Payments from drug & device makers
Across 285 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$809
- Sanofi-aventis U.S. LLC$525
- AstraZeneca$435
- Amgen$393
- Novartis$343
- Merck$340
- plus $3K from 27 others
What the payments were for
- Food & beverage$5,29998%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $809 |
| Sanofi-aventis U.S. LLC | 32 | $525 |
| AstraZeneca | 27 | $435 |
| Amgen | 15 | $393 |
| Novartis | 18 | $343 |
| Merck | 21 | $340 |
| Johnson & Johnson | 17 | $298 |
| GSK | 12 | $289 |
| Boehringer Ingelheim | 12 | $244 |
| Astellas Pharma US Inc | 4 | $238 |
| Lilly USA, LLC | 11 | $188 |
| Pfizer | 9 | $175 |
| Bayer | 11 | $174 |
| AbbVie | 8 | $127 |
| Valeritas, Inc. | 2 | $103 |
| Abbott | 5 | $103 |
| Insulet Corporation | 6 | $94 |
| Exact Sciences | 5 | $72 |
| Xeris Pharmaceuticals, Inc. | 4 | $68 |
| Zealand Pharma US, Inc. | 2 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Medicure Pharma Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $15 |
| Boston Scientific | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$125
- TRELEGY ELLIPTA$119
- Repatha$113
How this compares
$5,411 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $94,778 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 66 | $94,310 |
| OzempicSemaglutide | 63 | $66,378 |
| MounjaroTirzepatide | 55 | $62,529 |
| EliquisApixaban | 67 | $57,641 |
| FarxigaDapagliflozin Propanediol | 72 | $53,730 |
| XareltoRivaroxaban | 52 | $46,863 |
| JardianceEmpagliflozin | 48 | $38,231 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $33,327 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $30,661 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $19,446 |
| RybelsusSemaglutide | 18 | $18,182 |
| EntrestoSacubitril/Valsartan | 19 | $17,601 |
| Repatha SureclickEvolocumab | 20 | $16,800 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $16,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $289 | $111,442131 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $525 | $94,31066 claims |
| Novo NordiskOzempic, Rybelsus | $809 | $84,56081 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $244 | $71,55885 claims |
| Lilly USA, LLCMounjaro | $188 | $62,52955 claims |
| PfizerEliquis | $175 | $57,64167 claims |
| AstraZenecaFarxiga | $435 | $53,73072 claims |
| Johnson & JohnsonXarelto | $298 | $46,86352 claims |
| NovartisEntresto | $343 | $17,60119 claims |
| Astellas Pharma US IncMyrbetriq | $238 | $8,21119 claims |
| AbbVieSynthroid | $127 | $4,168123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Portland
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.